All In Biotech

Drug Trial Radar · NCT04010448

A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and India

A Phase 3 Double-blind, Randomized, Active Comparator-controlled, Group-sequential, Multinational Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants

Last checked: Nov 20, 2026Latest source record: Apr 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 8,200 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

8,200

Planned (sponsor's estimate)

Start

Oct 10, 2019

Primary completion

Dec 15, 2025

Study completion Dec 15, 2025

Sponsor

Lead sponsor
PATHAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bill and Melinda Gates Foundation; SK Bioscience Co., Ltd.
First posted
Jul 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 weeks, up to 8 weeks
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The trial will be a multinational, randomized, double-blind, double-dummy, endpoint driven, group-sequential, active comparator-controlled study, in which participating infants will be randomized 1:1 to receive either: 1) 90 µg of the TV P2-VP8 vaccine IM plus oral placebo, or 2) Rotarix® per os (PO) plus IM placebo. Participants will receive three doses of TV P2-VP8/placebo IM and two doses of Rotarix®/placebo PO at monthly intervals starting at ≥6 to \<8 weeks of age, administered concomitantly with EPI/UIP vaccines. To maintain the blind, infants allocated to the TV P2-VP8 vaccine arm will receive both TV P2-VP8 IM as well as oral placebo vaccine, and infants allocated to receive Rotarix® will receive both Rotarix® PO and placebo IM. Active surveillance for episodes of gastroenteritis (GE) will be conducted throughout the study, through weekly contact with participants' parents. Unsolicited AEs grade ≥ 2 through 28 days after the last study vaccination will be recorded in the study database, as will data for SAEs (including intussusception) throughout the study.

Conditions

  • Rotavirus Infection of Children

Interventions

  • TV P2-VP8Biological

    90 µg of the TV P2-VP8 vaccine IM plus oral placebo administered on study days 1, 29 and 57

  • RotarixBiological

    Rotarix® PO plus IM placebo administered on study days 1, 29 and 57

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of laboratory confirmed cases of severe rotavirus gastroenteritis (SRVGE; any strain)Time frame: For cases with onset at least 2 weeks after 3rd study vaccination and onset at any time after first vaccination; for all events within the first 2 years of life
  2. Number of serious adverse events (SAEs), including intussusceptionTime frame: Through 28 days after the last dose of study vaccine
  3. Number of Adverse Events (AEs) > or = to grade 2Time frame: Through 28 days after the last dose of study vaccine

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Infectious Disease Research in Zambia (CIDRZ)

    Lusaka, Zambia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.